FDA 483 OBSERVATION · #131 OF 1,923 MOST-CITED
Design validation- Lack of or inadequate procedures
FDA cited this observation 231 times across 218 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The firm has not established, or has inadequately established, procedures for design validation — the activity that ensures devices conform to defined user needs and intended uses under actual or simulated use conditions, including software validation, risk analysis, and validation on initial production units or their equivalents.
Why FDA writes it — Design verification confirms outputs meet inputs; design validation confirms the finished device actually works for the patient and user. FDA protects against a device that is built exactly to specification yet still fails the clinical need, because validation was never defined or was reduced to a paperwork check.
- Write a design-validation procedure requiring validation against user needs and intended uses under actual or simulated conditions.
- Require validation on initial production units, lots, or their documented equivalents — not on engineering prototypes alone.
- Incorporate software validation and risk analysis (per §820.30(g)) into the validation plan where applicable.
- Tie validation acceptance to documented user needs so results are traceable to the intended use.
- The firm conflates verification with validation and never validates against real user needs.
- Schedule pressure pushes validation onto prototypes rather than production-equivalent devices.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.9× the rate of the average FDA-cited firm (14.7% vs 7.8%), across 218 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for design validation have not been adequately established.
Procedures for design validation have not been adequately established.
Procedures for design validation have not been adequately established.
Procedures for design validation have not been adequately established.
Procedures for design validation have not been adequately established.
Procedures for design validation have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →